Sarepta Therapeutics | SRPT - Net Income


Sarepta Therapeutics reported $330.96M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Tectonic Therapeutic USD -19.23M 186K Dec/2025
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026